Advertisement

Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma

  • Yangyang Wang
  • Francesco Sabbatino
  • Xinhui Wang
  • Soldano Ferrone
Part of the Methods in Molecular Biology book series (MIMB, volume 1102)

Abstract

The tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4) appears to be a useful biomarker to identify melanoma cells and an attractive target to apply antibody-based immunotherapy for the treatment of melanoma. Here we described the reverse transcription-polymerase chain reaction (RT-PCR) method and the immunohistochemical (IHC) staining method to detect the expression of CSPG4 in melanoma cells and tissues.

Key words

CSPG4 Melanoma RT-PCR IHC staining 

Notes

Acknowledgements

This work was supported by Susan G. Komen for the Cure Postdoctoral Fellowship Grant # KG111486; and by R01 CA110249 and R01-1CA138188 grants awarded by the National Cancer Institute.

References

  1. 1.
    Campoli M, Ferrone S (2009) Immunotherapy of malignant disease: the coming age of therapeutic monoclonal antibodies. In: DeVita V, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott Williams and Wilkins, New York, NY, pp 1–18Google Scholar
  2. 2.
    Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32PubMedCrossRefGoogle Scholar
  3. 3.
    Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 16:15–31PubMedCrossRefGoogle Scholar
  4. 4.
    Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Ann Rev Immunol 20:621–667CrossRefGoogle Scholar
  5. 5.
    Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 20:585–612PubMedCrossRefGoogle Scholar
  6. 6.
    Boross P, Leusen JH (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2:676–690PubMedGoogle Scholar
  7. 7.
    Okroj M, Österborg A, Blom AM (2013) Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev 39:632–639Google Scholar
  8. 8.
    Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24:267–296PubMedCrossRefGoogle Scholar
  9. 9.
    Campoli M, Ferrone S, Wang X (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Canc Res 109:73–121CrossRefGoogle Scholar
  10. 10.
    Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A et al (2010) CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Canc Inst 102:1496–1512CrossRefGoogle Scholar
  11. 11.
    Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI et al (2012) CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 18:5352–5363PubMedCrossRefGoogle Scholar
  12. 12.
    Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH et al (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10:419–429PubMedCrossRefGoogle Scholar
  13. 13.
    Marsden CG, Wright MJ, Pochampally R, Rowan BG (2009) Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Meth Mol Biol 590:363–375CrossRefGoogle Scholar
  14. 14.
    Visvader JE (2011) Cells of origin in cancer. Nature 469:314–322PubMedCrossRefGoogle Scholar
  15. 15.
    Morgan AC Jr, Woodhouse C, Bartholemew R, Schroff R (1986) Human melanoma-associated antigens: analysis of antigenic heterogeneity by molecular, serologic and flow-cytometric approaches. Mol Immunol 23:193–200PubMedCrossRefGoogle Scholar
  16. 16.
    Ziai MR, Imberti L, Nicotra MR, Badaracco G, Segatto O, Natali PG et al (1987) Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res 47:2474–2480PubMedGoogle Scholar
  17. 17.
    Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K et al (2011) Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res 71:7410–7422PubMedCrossRefGoogle Scholar
  18. 18.
    Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 89:466–470PubMedCrossRefGoogle Scholar
  19. 19.
    Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S (1995) Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Canc Res 1:705–713Google Scholar
  20. 20.
    McCabe RP, Quaranta V, Frugis L, Ferrone S, Reisfeld RA (1979) A radioimmunometric antibody-binding assay for evaluation of xenoantisera to melanoma-associated antigens. J Natl Cancer Inst 62:455–463PubMedGoogle Scholar
  21. 21.
    Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S (2005) Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol 174:7104–7110PubMedGoogle Scholar
  22. 22.
    Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S (2006) Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 25:2873–2884PubMedCrossRefGoogle Scholar
  23. 23.
    Chen ZJ, Yang H, Kageshita T, Ferrone S (1991) Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res 51:4790–4797PubMedGoogle Scholar
  24. 24.
    Wilson BS, Imai K, Natali PG, Ferrone S (1981) Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28:293–300PubMedCrossRefGoogle Scholar
  25. 25.
    Kusama M, Kageshita T, Chen ZJ, Ferrone S (1989) Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 143:3844–3852PubMedGoogle Scholar
  26. 26.
    Perosa F, Ferrone S (1988) Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11–462. Hum Immunol 23:255–269PubMedCrossRefGoogle Scholar
  27. 27.
    Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8:85–95PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Yangyang Wang
    • 1
  • Francesco Sabbatino
    • 1
  • Xinhui Wang
    • 1
  • Soldano Ferrone
    • 2
  1. 1.Department of SurgeryMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.Department of Surgery and Orthopaedic SurgeryMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations